



Have you considered a quick and simple opportunity to reduce your respiratory prescribing budget?

Consider NACSYS[®] instead of carbocisteine as your first-choice mucolytic in COPD patients.

Oral mucolytics may present a medicines optimisation opportunity, benefitting patients and the local prescribing budget.

More than **fifty-seven** Medicines Management Organisations across the UK have already chosen NACSYS[®] as either their only mucolytic option in COPD, or as an alternative first-line choice for carbocisteine¹.

NACSYS[®] used as a first-choice mucolytic could deliver savings to your organisation and save the NHS over £8.6m annually²

NACSYS[®] significantly reduces tablet burden compared to carbocisteine³

NACSYS[®] is a convenient once daily effervescent mucolytic³

NACSYS[®] is simple to use as it requires no dose titration³

If you would like to know more about these potential efficiency savings for your organisation, please email us at info@alturix.com or scan this QR code to receive a copy of our Budget Impact Model.



Abridged Prescribing Information

Product name: NACSYS 600mg effervescent tablets.

Composition: Each effervescent tablet contains 600mg of acetylcysteine and sodium hydrogen bicarbonate (E500) which is equivalent to 115mg of sodium.

Therapeutic Indication: NACSYS is indicated for use as a mucolytic in adults with respiratory disorders.

Posology: One effervescent tablet of 600mg to be taken once daily.

Method of Administration: Dissolve NACSYS 600mg effervescent tablets in half a glass of water to produce a solution that can be consumed immediately. Patients with a reduced cough reflex (elderly and weakened patients) are advised to take the tablet in the morning.

Contraindications: Hypersensitivity to acetylcysteine or to any of the excipients. The tablets should not be used by children under two years of age.

Special warnings and precautions: Bronchospasm may occur with the use of NACSYS. Treatment with NACSYS should be discontinued immediately if this occurs. The administration of NACSYS may liquefy bronchial secretions and increase their volume. If the patient is unable to expectorate efficiently, postural drainage and bronchoaspiration should be used.

Interactions: Antitussive drugs and acetylcysteine should not be administered concomitantly. Activated charcoal may reduce the effect of acetylcysteine. It is precautionary to advise against the administration of oral antibiotics for at least two hours before or after acetylcysteine. Concurrent administration of acetylcysteine with nitroglycerine may enhance its vasodilatory effect. Acetylcysteine can interfere with the colorimetric assay for the determination of salicylates.

Pregnancy & Lactation: If necessary, NACSYS 600mg may be used during pregnancy and lactation although there are limited data about its use.

Undesirable effects: Common (>1/100) undesirable effects have not been reported. Uncommon (≥1/1000<1/100) Hypersensitivity headache; tinnitus; tachycardia; hypotension, gastrointestinal reaction (vomiting, diarrhoea, stomatitis, abdominal pain, nausea); fever. Rare (>1/10000<1/1000): dyspepsia; Very rare (<1/100000): anaphylactic shock, anaphylactic reaction, haemorrhage; serious skin reactions such as Stevens-Johnson syndrome and Lyell's syndrome have very rarely been reported in temporal connection with the use of acetylcysteine. Prescribers should consult the Summary of Product Characteristics in relation to other adverse effects.

Reporting adverse effects: Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Alturix Limited at safety@alturix.com and +44 (0)1908 038 083

NHS price: £5.50 for a pack of thirty effervescent tablets.

Legal classification: POM

Distributor: Alturix Limited, 287 Upper Fourth Street, Milton Keynes, MK9 1EH, UK

MA number: PL 44490/0006

Date of revision of the text: October 2020

Job Code: AL0139